Effect of cyclosporine and Sirolimus on interleukin-15-driven proliferation of OKT3-preactivated human lymphocytes.
Degiannis
D
D
Onassis Cardiac Surgery Center, Molecular Immunopathology and Histocompatability Laboratory, Athens, Greece.
Kalteziotis
V
V
Thalassinos
A
A
Kapsalis
A
A
Kroupis
C
C
Koniavitou
K
K
D002478:Cells, Cultured; D016572:Cyclosporine / Q000494:pharmacology*; D006801:Humans; D007166:Immunosuppressive Agents / Q000494:pharmacology*; D019409:Interleukin-15 / Q000494:pharmacology*; D007376:Interleukin-2 / Q000494:pharmacology; D007700:Kinetics; D008213:Lymphocyte Activation / Q000187:drug effects / Q000276:immunology*; D008214:Lymphocytes / Q000187:drug effects* / Q000276:immunology; D016853:Muromonab-CD3 / Q000494:pharmacology*; D011090:Polyenes / Q000494:pharmacology*; D011994:Recombinant Proteins / Q000494:pharmacology; D020123:Sirolimus; D013997:Time Factors
D007166:Immunosuppressive Agents; D019409:Interleukin-15; D007376:Interleukin-2; D016853:Muromonab-CD3; D011090:Polyenes; D011994:Recombinant Proteins; D016572:Cyclosporine; D020123:Sirolimus